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Abstract
Background: Cerebral malaria (CM) is a neurological syndrome that includes coma and seizures following malaria parasite
infection. The pathophysiology is not fully understood and cannot be accounted for by infection alone: patients still
succumb to CM, even if the underlying parasite infection has resolved. To that effect, there is no known adjuvant therapy for
CM. Current murine CM (MCM) models do not allow for rapid clinical identification of affected animals following infection.
An animal model that more closely mimics the clinical features of human CM would be helpful in elucidating potential
mechanisms of disease pathogenesis and evaluating new adjuvant therapies.
Methodology/Principal Findings: A quantitative, rapid murine coma and behavior scale (RMCBS) comprised of 10
parameters was developed to assess MCM manifested in C57BL/6 mice infected with Plasmodium berghei ANKA (PbA). Using
this method a single mouse can be completely assessed within 3 minutes. The RMCBS enables the operator to follow the
evolution of the clinical syndrome, validated here by correlations with intracerebral hemorrhages. It provides a tool by
which subjects can be identified as symptomatic prior to the initiation of trial treatment.
Conclusions/Significance: Since the RMCBS enables an operator to rapidly follow the course of disease, label a subject as
affected or not, and correlate the level of illness with neuropathologic injury, it can ultimately be used to guide the initiation
of treatment after the onset of cerebral disease (thus emulating the situation in the field). The RMCBS is a tool by which an
adjuvant therapy can be objectively assessed.
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Introduction
Malaria kills 1–2 million people per year, mostly children under
the age of 5 in sub-Saharan Africa [1,2]. The protozoan parasite
Plasmodium falciparum is the most common cause of malaria in the
world, and by far, the most debilitating and deadly phenotype of
malaria is the neurological syndrome cerebral malaria (CM) [3].
At the point of diagnosis, the decline in health is rapid and 10%–
20% of treated patients die, often within 24–72 hours after the
onset of illness, and 10–15% of survivors are left with neurological
sequelae [4,5]. The pathophysiology of CM is not fully
understood, and at present there is no known effective adjuvant
therapy.
CM is diagnosed clinically using the criteria set forth by the
World Health Organization (WHO): (1) an encephalopathic state
with a Glasgow Coma Score (GCS) of 11 out of 15, or less for
adults, or a Blantyre Coma Scale (BCS) of 2 out of 5, or less, for
children; (2) verified Plasmodium parasitemia; (3) exclusion of
potential confounding factors such as hypoglycemia, on-going
seizures, and/or other CNS infections [6]. Human CM has been
described to involve multiple types of CNS dysfunction, including
encephalopathy, posturing, seizures, and coma [6,7].
A well-described mouse model involves a CM-susceptible strain
(C57BL/6) infected with the rodent malaria parasite, Plasmodium
berghei ANKA (PbA) [8]. A proportion of infected subjects develop
neurological symptoms and rapidly progress to death within 5 to
10 days of infection, in the face of relatively low parasitemia. In
principle, the MCM can be used to study the mechanisms of CM,
and to identify and validate new therapeutic targets using clinically
relevant disease endpoints. The use of the MCM models has been
limited in part by the lack of a rapid scoring system used to
objectively assess functional neurologic impairment.
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the need for a model to emulate the human CM scenario, we have
developed a rapid murine coma and behavior scale (RMCBS).
This score utilizes 10 parameters and can be used to assess a
subject mouse under 3 minutes, thus allowing a large number of
mice to be studied in one experiment, providing the level of
throughput and power needed to determine medication efficacy in
adjuvant therapy trials. The level of illness, as objectively
determined by the RMCBS, was corroborated by inter-operator
validation, and was significantly correlated with intracerebral
pathology. The RMCBS can be used to objectively label a mouse
as affected, or not, providing a starting point for adjuvant therapy
trials. This assessment method more closely emulates the situation
in the field and attempts to bring the animal model closer to the
human disease.
Results
Establishment of the RMCBS and its utilization to
measure murine cerebral malaria induced by P. berghei
ANKA infection
The RMCBS consists of ten (10) parameters (see Table 1, and
Supporting Information Video S1/Video S2), each scored from 0
as the lowest, to 2 as the highest, with a maximum possible score of
20. We utilized parameters similar to components of the SHIRPA
score [9,10], using only those that reflect real-time CNS function,
and those that could be assessed within seconds. The final product
is the RMCBS, a tool by which each mouse could be assessed in
three minutes, or less, in two steps of 90 seconds each, as described
below.
In the initial 90 seconds, mice were assessed for hygiene-related
behavior, gait, body position, exploratory behavior, and balance
(Table 1). Thus, a mouse was scored as healthy in the presence of:
(i) smooth, preened hair with sheen (ii) a steady gait (iii) full
extension of its body as it sat and walked (iv) explored all four
corners of the grid box in under 15 seconds and (v) reached the
top of the grid box and pulled itself to the edge, lifting its hind legs
off the cage floor. In contrast, an ill mouse respectively developed
(i) piloerection, and later complete disarray of its hair (ii) ataxia, or
no gait (iii) remained in a crouched position, even while walking,
and later lay on its side (iv) explored only three, or fewer corners in
90 seconds, and later did not move from the original corner and
(v) placed only its forelegs on the cage edge and later ceased to
raise the forelegs altogether.
In the next 90 seconds, mice were assessed for reflexes, limb
strength, and self-preservation behaviors (Table 1). A healthy
mouse (i) jumped away from the stimulus of a touch to its flank,
often on the first offense, and certainly within three attempts made
on each side (ii) flicked its ear when the pinna was touched (iii)
grasped a 3-mm diameter rod and pulled away (iv) reflexively
pulled its hind leg away from a toe pinch while suspended with the
front paws grasping the rod and (v) bit at the retention tube and
restraining ring when secured for the purposes of tail blood
sampling. An ill mouse would respectively demonstrate (i, ii, iv,
and v) fewer to no reflexive movements with stimulation, and (iii)
would not pull away when suspended, eventually refusing to grasp
the 3-mm diameter rod.
To address operator bias, the score was independently validated
via video (Table 2). An initial operator (Operator 1: Op 1) scored
two symptomatic mice and one asymptomatic control mouse,
using the RMCBS, while videotaping the procedure. A second
operator (Operator 2: Op 2), blinded to the score and category of
the subject (control versus experimental), viewed the video and
provided a score. Grooming was the only parameter difficult to
capture on film and was not included in this validation; therefore,
the highest achievable RMCBS total score was 18. The final
scores, when compared between Op 1 and Op 2 resulted in a
Krippendorff’s alpha of 0.86.
To demonstrate the time course of MCM using the RMCBS,
we daily assessed experimental mice infected with PbA (n=16)
and non-infected control (n=3) (Figure 1). The representative
number of experimental mice, per day of infection, during the
rapid decline in RMCBS were as follows: Day 5, n=16; Day 6,
n=16; Day 7, n=8 (50% mortality from the previous day); Day 8,
Table 1. The Rapid Murine Coma and Behavior Scale (RMCBS).
Label Score Description
Coordination
Gait (0–2) (none – ataxic – normal)
Balance (0–2) (no body extension – extends front feet on wall – entire body lift)
Exploratory Behavior
Motor Performance (0–2) (none – 2–3 corners explored in 90 seconds – explores 4 corners in 15 seconds)
Strength and Tone
Body Position (0–2) (on side – hunched – full extension)
Limb Strength (0–2) (hypotonic, no grasp – weak pull-back[front paw grasp only] – strong pull-back[active pull away, jerk away])
Reflexes and Self-Preservation
Touch Escape (0–2) (none – unilateral – instant and bilateral; in 3 attempts)
Pinna Reflex (0–2) (none – unilateral – instant and bilateral; in 3 attempts)
Toe Pinch (0–2) (none – unilateral – instant and bilateral; in 3 attempts)
Aggression (0–2) (none – bite attempt with tail cut – bite attempt prior to tail cut, in 5 seconds)
Hygiene-Related Behavior
Grooming (0–2) (ruffled, with swaths of hair out of place – dusty/piloerection – normal/clean with sheen)
The RMCBS consists of 10 parameters, and each parameter is scored 0 to 2, with a 0 score correlating with the lowest function and a 2 score, the highest. An animal can
achieve an accumulative score of 0 to 20.
doi:10.1371/journal.pone.0013124.t001
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scores between 12 and 15 developed a rapid decline in score, and
ultimately became moribund within 24 hours.
As shown in Figure 1, the RMCBS score shows a declining
linear and quadratic trend for the control and experimental group,
respectively. In order to accommodate the different trends in the
two groups, we fit a regression with both linear and quadratic
terms, resulting in the following models (for mouse i on day j):
Control group: RMCBSij~18:44{0:036| dayij{4:06
 2
zeij
Experimental group: RMCBSij~19:58{0:715| dayij{2:15
 2
zeij
These equations render a difference in the slopes of the two groups
(p=0.0001), and t-test evaluation reveals a significant difference in
the mean RMCBS scores on the final day of the experiment (day
8; remaining experimental mice, n=3, mean RMCBS 4.6767.23
SD versus control, n=3, mean RMCBS 17.6761.53 SD,
p=0.04).
The mice became symptomatic despite low parasitemia levels,
with a mean level of 3.5% on day 5 of infection and a peak mean
level of 11.8% on day 8 of infection (range of 5.1%–8.8% on day 8
of infection, with an outlier of 37.3%) (Figure 2).
Over the course of 5 experiments, we found that 36 of 40 (90%)
of infected mice developed symptoms consistent with MCM
between days 5 and 9 of infection, with a range of final RMCBS
scores of 0 to 7 (mean 3.0), and a mean final parasitemia of 9.2%
(range of 3.5%–37.3%; mean 7.6% without outliers greater than
Table 2. Comparison of RMCBS scores between two
operators.
Label Score Mouse 1 Mouse 2 Mouse 3
Op 1 Op 2 Op 1 Op 2 Op 1 Op 2
Coordination
Gait (0–2) 1 1 2 2 2 2
Balance (0–2) 0 0 0 0 2 2
Exploratory Behavior
Motor Performance (0–2) 0 0 1 2 2 2
Strength and Tone
Body Position (0–2) 1 1 1 1 2 2
Limb Strength (0–2) 1 1 2 2 2 2
Reflexes and Self-Preservation
Touch Escape (0–2) 1 0 1 1 2 2
Pinna Reflex (0–2) 0 0 2 2 2 2
Toe Pinch (0–2) 0 2 1 2 2 2
Aggression (0–2) 0 0 2 2 2 2
Hygiene-Related Behavior
Grooming (0–2) 1 N/A 1 N/A 2 N/A
Total with grooming (0–20) 5 N/A 13 N/A 20 N/A
Total without grooming (0–18) 4 5 12 14 18 18
Symptomatic mice (severe and mild, Mouse 1 and 2, respectively) and a non-
infected asymptomatic mouse (Mouse 3) were assessed and videotaped.
Operator 1 (Op 1) assessed in real time, while Operator 2 (Op 2) assessed via
video footage. Krippendorff’s alpha of 0.86.
doi:10.1371/journal.pone.0013124.t002
Figure 1. Mean RMCBS and day of infection curves. These data represent the typical trajectory of disease in the MCM model, as highlighted by
the RMCBS. Lightly colored lines represent individual subjects, and the two darker lines represent the mean scores from the experimental mice (red
dashed line, n=16) and the control mice (blue dotted line, n=3). Comparing the mean RMCBS curves was significant, p,0.0001, and the t-test to
assess the difference in RMCBS at day 8 of infection was also significant, p=0.04.
doi:10.1371/journal.pone.0013124.g001
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on MCM outcomes [9,10,11]. The 4 asymptomatic mice (non-
MCM) demonstrated a RMCBS range of 13–16 (mean 14.3) on
the day of sacrifice (day 6–9) with a mean parasitemia of 5.4%
(range 3.4%–9.6%). There was no significant difference in the
parasitemia levels of the symptomatic and asymptomatic MCM
mice (p=0.21 and 0.11, with and without outliers of parasitemia
.20%, respectively) (Figure 3A and 3B). Using Tukey-Kramer’s
method to adjust for multiple comparisons, the pair-wise
assessments are as follows: comparing the final RMCBS of
symptomatic MCM mice with control, the mean difference was
214.6 (95%CI 216.4 to 212.7, p,0.0001); the symptomatic
MCM mice with asymptomatic MCM mice, the mean difference
was 211.3 (95% CI 213.9 to 28.7, p,0.0001); and the
asymptomatic MCM mice with the control mice, the mean
difference was 23.3 (95% CI 26.3 to 20.3, p=0.027) (Figure 3C).
The utilization of the RMCBS allowed us to consistently and
accurately follow the trajectory of the MCM disease process in
each of these experiments, thus demonstrating reproducibility and
speed.
Data from the previous experiments showed the greatest decline
in the RMCBS between days 5 and 8 of infection (Figure 1). To
determine more precisely the time course of clinical deterioration
within this window, we next quantified the RMCBS at more
frequent intervals (Figure 4). Twelve C57BL/6 mice with P. berghei
ANKA infections and 3 non-infected control mice were followed
daily via RMCBS and parasitemia. When the subjects began
demonstrating symptoms, on day 6 of infection, we assessed the
mice more frequently, as follows: if the RMCBS score was 16–20,
mice were assessed every 12 hours; if the RMCBS score was 11–
15, mice were assessed every 4 hours; if the RMCBS score was 6–
10, mice were assessed every 2 hours; and if the RMCBS score
was #5, the mice were considered moribund and were sacrificed.
For clarity, we provide a representative figure including 4
experimental mice and one control mouse in Figure 4. We did
not report these findings via mean RMCBS to demonstrate the
mouse-to-mouse variability and individual disease curves.
To further assess the value of the RMCBS to follow the
trajectory of illness specific to the MCM model, we inoculated a
known MCM-resistant mouse strain, balb/c, with PbA [12,13,14]
and followed the disease progress via the RMCBS. In addition, we
utilized the RMCBS to follow the C57BL/6 mice infected with
PbA that did not develop symptoms of MCM, but rather survived
over a week, developing high parasitemia. Figure 5 shows the
mean RMCBS score for non-infected control C57BL/6 (n=2,
parasitemia 0%, intracerebral hemorrhages 0), symptomatic
infected C57BL/6 mice (n=3, peak parasitemia 6.2% on day 7,
intracerebral hemorrhages 18–102), an asymptomatic infected
C57BL/6 mouse (n=1, peak parasitemia 42% on day 15,
intracerebral hemorrhages 0), as well as non-infected control
balb/c mice (n=2, parasitemia 0%, intracerebral hemorrhages 0),
and infected balb/c mice (n=4, peak parasitemia 54.3% on day
14, intracerebral hemorrhages 0). There is a significant difference
when comparing the mean RMCBS slopes of symptomatic
infected C57BL/6 and infected balb/c (p=0.01); a significant
difference when comparing symptomatic infected C57BL/6 and
Figure 2. Parasitemia levels in experimental and control mice. Mice inoculated with PbA, as well as non-inoculated controls, were followed
daily for parasitemia levels. Mean parasitemia on day 5 was 3.5%, with a peak of 11.8% on day 8 (including an outlier of 37%). Light gray lines
represent individual subjects, and the two darker lines represent the mean levels from the experimental mice (dark dashed line, n=16) and the
control mice (dark dotted line, n=3).
doi:10.1371/journal.pone.0013124.g002
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cant difference (p=0.06) when comparing symptomatic infected
C57BL/6 with asymptomatic infected C57BL/6; a non-significant
difference when comparing infected balb/c and non-infected
control balb/c (p=0.48); and a non-significant difference
(p=0.70) when comparing infected balb/c with asymptomatic
infected C57BL/6 and non-infected control C57BL/6. Figure 6
demonstrates the parasitemia curves for these same cohorts. Two
experimental balb/c mice and one non-infected control balb/c
mouse were sacrificed on day 7 to determine the presence of
intracerebral hemorrhages. The RMCBS clearly delineates the
rapid decline in the health of the experimental infected C57BL/6
mice. Note that the RMCBS follows the steady decline of the
balb/c mice; however, the difference between the control and
Figure 4. Increased frequency in surveillance via RMCBS. Mice were rapidly assessed at frequent intervals on day 6 of infection via the RMCBS,
allowing the operator to closely follow the trajectory of disease progression.
doi:10.1371/journal.pone.0013124.g004
Figure 3. Overall outcome data. A and B. Compared cumulative parasitemia data from 5 experiments involving symptomatic MCM versus
asymptomatic infected mice, p=0.21 and 0.11, with (A) and without (B) outliers of parasitemia .20%, respectively. C. Cumulative RMCBS data from
the same 5 experiments. Pair-wise comparison of symptomatic MCM mice versus control: mean difference 214.6 (95%CI 216.4 to 212.7, p,0.0001);
the symptomatic MCM versus asymptomatic: mean difference 211.3 (95% CI 213.9 to 28.7, p,0.0001); and the asymptomatic MCM versus control
mice: mean difference 23.3 (95% CI 26.3 to 20.3, p=0.027). Tukey-Kramer’s method was used to adjust for multiple comparisons.
doi:10.1371/journal.pone.0013124.g003
RMCBS for Murine CM
PLoS ONE | www.plosone.org 5 October 2010 | Volume 5 | Issue 10 | e13124infected experimental balb/c mice is not as specific as in the
C57BL/6 mice, making the RMCBS unsuitable for models
utilizing the balb/c mice, and better suited for the MCM model.
Correlating the RMCBS with histopathology
Next, we investigated whether there was a correlation between
the reduction in RMCBS and a concomitant increase in
intracerebral hemorrhages, a known CNS pathology in MCM
(See Figure 7). Hemorrhages were counted by an operator
blinded to the clinical condition of the mouse, and were defined
as a well-circumscribed collection of RBCs (10 to 100s) in the
brain parenchyma, not associated with a blood vessel. The
number of hemorrhages detected ranged from none (in non-
infected control and infected asymptomatic mice) and 1 to 529 in
symptomatic infected experimental mice. Figure 8A demonstrates
a strong negative correlation between the number of hemorrhag-
es and the RMCBS score on the day of sacrifice. Utilizing raw
values of the RMCBS, the Spearman Correlation coefficient
between hemorrhagic counts and RMCBS was 20.64,
(p=0.0001). While significant, this Spearman Correlation may
only be 20.64 because the number of hemorrhages is only one
metric. It stands to reason that the greater the number of
hemorrhages, the greater likelihood the subject will develop
pathology. However, a single hemorrhage located in an area vital
to central functions, namely respiratory drive (i.e., brainstem and
the medulla oblongata), can lead to terminal respiratory failure. It
is likely that the location of the hemorrhages is just as important
as the total number.
When mice are dichotomized according to the RMCBS, mice
achieving a RMCBS of 0–15 (n=6) demonstrate a total
hemorrhage count of 1014, versus the cohort achieving a RMCBS
of 16–20 (total n=22 minus 6 control=16 experimental) with a
total hemorrhage count of 59 (p,0.0001, Mann-Whitney U)
(Figure 8B). To reinforce that infected subject animals will develop
an increasing number of hemorrhages as the infection progresses,
we demonstrate a positive correlation between the day of sacrifice
and the number of hemorrhages (Spearman Correlation=0.776,
p,0.0001, not including control mice, which were expected to
lack hemorrhages regardless of the day sacrificed) (Figure 9).
Detectable parasitemia levels on the day of sacrifice ranged
from 0.1% to 7.1%. Note that mice with documented infections,
while demonstrating a high RMCBS (.15) still demonstrated
intracerebral hemorrhages. In fact, one experimental mouse
sacrificed early in the experiment (day 4) demonstrated intrace-
rebral hemorrhages, but had not yet demonstrated the clinical
phenotype, nor did it have a detectable level of parasitemia. In
brains taken from mice with low RMCBS (#12), hemorrhages
were seen in all areas of the brain, representing Bregma +5
through 29. Anatomical locations in which hemorrhages were
consistently found include: olfactory bulb, motor cortex, medulla,
pons, brainstem, and the cerebellum. Data from two experimental
mice were not included because one did not develop infection, and
a second was found dead and the brain tissue was uninterpretable.
Only one experimental mouse was sacrificed on day 10 (RMCBS
4, parasitemia 4.9%, hemorrhage count 107). The other mice
intended to be sacrificed in this cohort all became moribund on earlier
Figure 5. Variable RMCBS outcomes. Mean RMCBS curves for MCM-susceptible mice (C57BL/6, n=3), an asymptomatic C57BL/6 mouse (n=1),
infected MCM-resistant mice (balb/c, n=4), and non-infected control C57BL/6 (n=2) and balb/c mice (n=2). Comparing slopes of mean RMCBS
curves: infected C57BL/6 versus infected balb/c (p=0.01); infected C57BL/6 versus non-infected C57BL/6 controls (p=0.004); symptomatic infected
C57BL/6 versus asymptomatic infected C57BL/6 (p=0.06, marginally significant); infected balb/c versus non-infected control balb/c (p=0.48); and
infected balb/c versus asymptomatic infected C57BL/6 and non-infected control C57BL/6 (p=0.70).
doi:10.1371/journal.pone.0013124.g005
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note, the parasitemia for this experiment was slow to rise: 0%–0.1%
by day 5, and 0%–1.6% by day 6. It can be argued that there is a
cascade of cellular-molecular pathophysiology that is triggered by a
threshold level of parasitemia. This may be a reason why clinical
pathology, histopathology, and lower RMCBS scores were not seen
until days 8, 9, and 10. This variable in the MCM model is another
reason why the RMCBS should be used to assess the level of disease.
Empirically introducing an adjuvant therapy on day 5 of infection
may lead to falsely reassuring outcomes because the parasitemia and
cellular-molecular pathophysiology have yet to fully develop.
Evaluation of an antimalarial drug using the RMCBS as a
guide for treatment
In a preliminary experiment on the utilization of the model, we
examined the effectiveness of the RMCBS in chloroquine treated
mice (Figure 10). To do this we had to select a RMCBS score at
which to initiate treatment. In prior experiments, none of the
control mice developed a score less than 15 (see Figure 1). In
addition, any infected mouse that developed a RMCBS score of 12,
or less, became moribund within 24–48 hours; none spontaneously
recovered from a disease state with such a low score. Therefore we
chose a conservative cut-off score of 12 to label mice with MCM,
providinga threshold fortreatment. Thus symptomaticanimalsthat
developed a RMCBS score of 5–12, within the experimental period
of 5–9 days were eligible for treatment. Mice that presented with a
score of 5, or less, were euthanized.
Categories of mice involved in this experiment are summarized
as follows: Non-Infected Controls (NIC, n=6); Experimental
Viable Treated (EVT, n=5); Infected Non-Treated Controls
(INTC, n=15). EVT and INTC mice (total n=20) were
inoculated with PbA as described above, 15 of which demonstrat-
ed a RMCBS score consistent with a moribund state, were thereby
labeled INTC, left untreated, and were euthanized. Five mice with
RMCBS#12, who were not moribund, were treated with
chloroquine (thus labeled EVT). Four mice of the EVT group
ultimately succumbed, having been treated on days 6, 6, 8, and 9,
Figure 7. Intracerebral hemorrhage in a symptomatic mouse.
PbA-infected mouse with final RMCBS of 5, H&E at 10006, bar=80-
micrometers.
doi:10.1371/journal.pone.0013124.g007
Figure 6. Parasitemia curves. Mean parasitemia curves for symptomatic MCM-susceptible mice (C57BL/6), MCM-resistant mice (balb/c), an
asymptomatic MCM mouse (C57BL/6), and non-infected control mice (C57BL/6 and balb/c).
doi:10.1371/journal.pone.0013124.g006
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mice developed a RMCBS of 5, or lower, the day following the
initiation of treatment and were euthanized or died. The fifth EVT
mouse was treated on day 7, at a RMCBS score of 11,
demonstrating a RMCBS nadir of 7 the following day, ultimately
making a full recovery. This mouse also developed complete
resolution of its parasitemia (peak parasitemia on the initial day of
treatment was 5.2%). Overall, this represents a mortality rate of
Figure 8. Correlation between RMCBS and number of hemorrhages. A. Mice were serially sacrificed on days 2, 4, 6, 8, 9 and 10,
demonstrating a strong negative correlation between the number of intracerebral hemorrhages and the RMCBS score on the day of sacrifice,
r=20.64 (p=0.0001, experimental n=22, control n=6). B. Comparing the total number of hemorrhages in cohorts of mice that scored between 16–
20 versus 0–15 (p,0.0001, Mann-Whitney U). Red crosshairs=mean RMCBS.
doi:10.1371/journal.pone.0013124.g008
Figure 9. Hemorrhages and day of sacrifice. Intracerebral hemorrhage tally in experimental mice versus day at which subject was sacrificed,
demonstrating a positive correlation. Spearman Correlation=0.776, p,0.0001.
doi:10.1371/journal.pone.0013124.g009
RMCBS for Murine CM
PLoS ONE | www.plosone.org 8 October 2010 | Volume 5 | Issue 10 | e1312480% in the EVT group, despite treatment. In contrast, 100% of
the INTC mice died, or were euthanized when found moribund.
The data in Figure 10 shows the trajectory of the mean RMCBS
between these different groups. For clarity, four mice that were
intended for the INTC and EVT groups that did not develop
infection (n=2) or were infected but asymptomatic (n=2) were
not included in these results. The RMCBS, however, did
accurately reflect the disease state of these animals: high normal
($19) for uninfected mice, and low normal ($14) for infected
asymptomatic mice.
All animals in the EVT and INTC groups demonstrated
intracerebral hemorrhages, assessed as described above, using 6
H&E-stained sagittal sections per mouse. The mice from the
INTC group demonstrated a range of 1–243 hemorrhages (mean
42, peak parasitemia range of 1.9%–12.1%). This hemorrhage
count does not include 3 INTC mice whose brain tissues were
considered uninterpretable. The mice from the EVT group
demonstrated a range of 23–108 hemorrhages (mean 51, peak
parasitemia range of 4.2%–5.9%). Of note, the animal that
survived in the EVT group (peak parasitemia 5.2%) was treated at
an RMCBS of 11, and demonstrated only 3 small intracerebral
hemorrhages on post-mortem inspection (Figure 11). These data
further demonstrate that the score is closely associated with
histological evidence of damage. This suggests that there may be a
threshold in the number of hemorrhages that leads to a rapid
decline in the subject’s health, pushing the subject to become
moribund. This further reinforces that an adjuvant therapy is
needed to help reduce the mortality of CM. The RMCBS may
facilitate studies designed to utilize disease trajectory to help
identify the optimal window for treatment.
Discussion
Until a safe and effective adjuvant therapy is discovered, CM
will remain the most virulent and deadliest clinical manifestation
of malaria. Twenty-percent of treated patients with CM succumb,
and most die within 24–48 hours. Human patients with CM often
come to medical attention well into coma, reflecting both the
rapidity by which CM is manifest as well as the socio-economic
challenges faced by the populations living in malaria-endemic
areas. By this time, a cascade of incompletely understood
pathological events is well underway. Adjuvant therapy trials in
humans aimed at halting these processes have not demonstrated
promising results [15]. More specifically, mannitol, steroids,
antipyretics, anti-seizure control, pentoxyfylline, and defuroxa-
mine, among others, have been proposed, used in limited
instances, or been shown to be detrimental, as in the case of
Figure 10. Outcome of chloroquine treatment of symptomatic mice with RMCBS#12. Mean RMCBS scores of Non-Infected Controls (NIC,
n=6); Experimental Viable Treated (EVT, n=5, peak parasitemia range 4.2%–5.9%, hemorrhage range 23–108 [mean 51]); Infected Non-Treated
Controls (INTC, n=15, peak parasitemia range 1.9%–12.1%, hemorrhage range 1–243 [mean 42]). An EVT animal received treatment on day 7 of
infection (at RMCBS of 11), clinically worsened (RMCBS 7 on day 8), but made a full recovery.
doi:10.1371/journal.pone.0013124.g010
Figure 11. Hemorrhage in recovered EVT mouse. Only three
small intracerebral hemorrhages were found on post-mortem exam-
ination of the EVT mouse that recovered (Figure 10), one of which is
demonstrated here (black arrow). H&E, 10006, bar=80-micrometers.
doi:10.1371/journal.pone.0013124.g011
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Mturi et al. [17]). An adjuvant therapy remains elusive.
Murine models of CM have been widely used to further
elucidate the pathophysiology of CM, as well as reveal potential
adjuvant therapies. To begin, major similarities and differences
between the MCM model and human CM have been described.
On a clinical basis, both MCM and human CM share phenotypes
of CNS dysfunction, including hemiparesis, seizures, coma, and a
rapid decline in health after the onset of illness (reviewed by Hunt
et al.) [18]. On the basis of histopathology, both share
intracerebral hemorrhages, histological signs of blood-brain
barrier dysfunction, and WBC sequestration [19,20,21]. Con-
versely, the finding of sequestered parasitized-RBC (pRBC) in the
cerebral vasculature remains consistent in human CM [22],
whereas this phenomenon is inconsistently reported in the MCM
model [18,23,24,25].
In light of these discrepancies, some authors have recently
questioned the merit of the MCM model [15]. However, multiple
authors contend that the MCM model, albeit imperfect, can be
used to enhance the study of human CM [26,27,28,29]. There is a
clear call for a MCM model that better emulates the human CM
condition.
A rapid murine assessment scale, as described in this study, is
imperative to emulating the human CM manifestation, while
providing operators with the ability to accurately label mice as
symptomatic, with a high degree of confidence of underlying
pathology, consequently providing a window during which rescue
and neuroprotective adjuvant therapies can be assessed.
Most MCM studies involve a binary evaluation of CM: the
subject is labeled affected, or not, using traditional descriptive
criteria [16,30,31,32]. A more objective neurological assessment
score, the SHIRPA protocol, has been developed for rodent
models [33,34,35,36], and has been applied to the MCM
[9,10,11,37,38], involving a maximum of 12 to 18 animals per
experiment [9,10,11]. It requires 40 parameters of observation,
and a complete assessment can take up to 20–30 minutes per
mouse, making this score time-consuming. Despite original
projections [33], this decreases the level of throughput and could
be considered suboptimal for frequently assessing a large number
of subjects and utilizing a threshold for treatment. We contend
that using this protracted score with larger numbers of animals in a
single cohort (n of 50 to 100) would prove difficult, especially when
introducing interventions during the short symptomatic period
(,24h) prior to death. Furthermore, aspects of the SHIRPA score
highlight processes in the mouse that are not directly attributable
to CNS dysfunction (i.e., defecation and urination frequency). In
an effort to focus the SHIRPA score, recent work by Martins et al.
[37] combines the SHIRPA score and logistic regression modeling
to predict the likelihood that a murine subject will develop fatal
CM. Of the 23 SHIRPA parameters with the highest predictive
yield that were assessed on days 5 and 6 of infection, all 10
corresponding parameters of the RMCBS are included. In parallel
to the work completed by Martins et al., we independently
developed the RMCBS as a tool to be used to quantitatively
recognize the development of murine CM in real time, validating
its use in adjuvant therapy trials.
To date, most trialed therapies have not been initiated after the
onset of MCM symptoms, making the conclusions less impactful.
Many authors have initiated empiric adjuvant therapy prior to, on,
or just after the first day of inoculation [11,39,40]. Alternatively,
empiric treatments have been provided around the proposed time
MCM symptoms have historically been documented to start, on
days 3 to 7, post-infection [30,39,41,42]. While the results of these
experiments have been promising, they do not fully emulate the
human clinical experience—patients are treated at the onset of
clinical symptoms, and often, much later. A murine-based model
of CM that better emulates the human CM experience is needed,
and it must include a neurobehavioral score that is rapidly
deployed.
We have developed the RMCBS to enhance the MCM model,
allowing the model to more closely emulate human CM. The
RMCBS allows an operator to quickly and objectively assess
multiple mice during the period in which the mice demonstrate a
rapid decline in health. The RMCBS can be used to establish the
time at which pharmacotherapy should be given, detect a response
to the therapy, correlate the clinical course with quantifiable
intracerebral histopathology, and ultimately trace the path to
recovery, making this score ideal for drug discovery for CM.
Because many patients with CM present to the hospital already
in coma, an adjuvant therapy that halts the pathological process is
desperately needed. In addition, at present, there is no way to
predict which malaria patient will plummet into CM, and which
will not. Perhaps a biomarker that reflects a patient’s risk of
developing CM can help guide prophylactic treatment. In parallel,
an adjuvant neuroprotective therapy is needed to curb the number
of children with long-term effects of CM. The RMCBS can be
used to guide further research endeavors aimed at discovering
these vital pieces of information.
Materials and Methods
Ethics Statement
All procedures were approved by the Northwestern University
and the University of Notre Dame IACUC committees.
Description of the RMCBS
The RMCBS consists of 10 parameters, and each parameter is
scored 0 to 2, with a 0 score correlating with the lowest function
and a 2 score, the highest. An animal can achieve an accumulative
score of 0 to 20. During the first 90 seconds of assessment, the
mouse is placed in the top left corner of an observation box
(length, 31.8 cm [12.5 in]; width, 19.8 cm [7.8 in]; height,
10.5 cm [4.1 in]) with a grid floor and is assessed for hygiene-
related behavior, gait, body position, exploratory behavior, and
balance. In the subsequent 90 seconds, the mouse is assessed for
reflexes, limb strength, and self-preservation actions. The tail
blood sampling for parasitemia is incorporated into the score
assessment. An illustrative table (Table 1) is provided for more
specific descriptions of the assessments. Furthermore, a video
recording of the score, useful for training, is available in the on-line
Supporting Information section (see Video S1 [low-resolution,
10.3MB]/Video S2 [high-resolution, 336MB]).
The murine model and RMCBS
The parasite strain Plasmodium berghei ANKA used in these
studies was supplied by MR4 (uncloned line MRA-311, depositor
Thomas McCutchan). A known CM-susceptible mouse strain was
used: 4–6 week old female C57BL/6 mice (C57BL/6NCRL from
Charles River Breeding Laboratories, Portage, Michigan, USA),
which were acclimated in the Research Resource Center of
Northwestern University for 2 weeks, per protocol, with food and
water ad libitum. Any mouse with obvious physical deformities or
size discrepancies was not included in the experiment. When the
mice reached 6–8 weeks of life, 16 experimental mice were
inoculated intraperitoneally (IP) with 1610
6 PbA (0.1mL) taken
from a homologue donor, which had been infected from frozen
stock. Four control mice were injected IP with 0.1mL of sterile
PBS. Each cage contained four experimental mice with one
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congenital growth retardation, leaving three control mice. Mice
were assessed via the RMCBS every 24 hours. Attempts were
made to assess the mice at the same time each day, usually the
evening hours, for every experiment; however, this was not always
achieved, and mice needed to be assessed frequently, at variable
times of the day. Blood was sampled daily from tail tip
phlebotomy, and parasitemia was determined by tabulating the
number of Giemsa-stained parasitized-RBCs out of a total of 500
RBCs, counted by a blinded operator using 406light microscopy.
Early experiments revealed that a mouse with a RMCBS of 5, or
less, would die within 1–4 hours, and such mice were labeled
moribund and were anesthetized with 10% pentobarbital IP. Mice
were exsanguinated via heart puncture and/or inferior vena cava
sever, and the brains were carefully excised and placed in pH-
balanced 10% formalin for 1–2 weeks.
We further assessed the effectiveness and specificity of the
RMCBS by comparing the trajectories of illness in subjects of a
non-MCM model and symptomatic and asymptomatic MCM
mice. We examined the RMCBS in PbA-infected C57BL/6
(known MCM-susceptible) mice and PbA-infected balb/c (known
MCM-resistant) mice. Experimental and control mice were
inoculated, assessed, and euthanized as described above. Intrace-
rebral hemorrhages were evaluated by an operator blinded to the
subject phenotype, viewing 5 H&E-stained sagittal sections under
406.
Brain histopathology and analyses
Brains were cut along the mid-sagittal line and the separated
hemispheres were positioned so that the newly cut surface was
presented, open-faced, to the microtome. The brains were then
fixed in paraffin blocks and 5-micrometer sections were cut along
the sagittal plane (interaural), so that both hemispheres were cut
side-by-side along the same anatomic plane and the juxtaposed
sections were placed on a glass slide. We obtained 5 such sections
per mouse, each separated by 40 micrometers, thus producing 10
sections per brain. Because the locations of predominant
pathology in MCM have yet to be fully delineated, we cut the
brain along the sagittal plane, thereby including all of the Bregma
positions, allowing the operator to visualize the entire brain
structure. Sections were stained with H&E and visualized with
light microscopy.
Correlating the RMCBS with histopathology
Twenty-four experimental mice were inoculated with PbA, and
6 control mice were injected with sterile PBS, and were assessed
daily, as described above. Cohorts of infected (n=4) and
uninfected mice (n=1) were sacrificed on days 2, 4, 6, 8, 9, and
10 after infection. Mice were euthanized and brains were excised
and sectioned as described above, with the following variation:
after euthanization and exsanguination, the head was removed at
the base of the cervical spine, the skin and fur removed, and the
whole head was placed in 10% formalin for 2 weeks. At that time,
after the tissue was well fixed, the brains were carefully excised and
placed in 10% formalin for 2 additional weeks. The brains were
then sectioned as described above. This resulted in 10 H&E-
stained sections, 5 of each hemisphere, for each mouse, which
were subsequently masked and coded, blinding the operator to the
clinical phenotype of the source mouse. The total number of
hemorrhages was tabulated for all ten sections per mouse. A
hemorrhage was defined as a clearly circumscribed collection of
blood within the brain parenchyma that was not a part of the
vascular system or part of an area of obvious trauma caused by
instrumentation. See Figure 7 for an example of a hemorrhage
seen in a symptomatic mouse.
Evaluation of an antimalarial drug using the RMCBS as a
guide for treatment
Twenty-four C57BL/6 mice were injected with PbA, as
described above, and when a mouse reached a score between 12
and 5, it was IP-injected with 0.3 mg of chloroquine IP, based on
an assumed 30-gram weight. These mice were treated daily with
IP chloroquine, receiving daily RMCBS and parasitemia assess-
ments. Mice were sacrificed when they became moribund
(RMCBS#5), or at the end of the experiment, on day 11. Non-
infected and infected control mice were inoculated and assessed
daily as described earlier, but were not treated with chloroquine.
The non-infected control mice were sacrificed at the end of the
experiment, on day 11. Brain handling, tissue staining, and
parasitemia assessment were carried out as described above.
Statistical Methods
To investigate the relationship between RMCBS and the day of
infection, we fit a random intercept random slope mixed model
with the RMCBS score as the outcome, and day of infection and
group assignment (i.e., experimental versus control) as covariates.
In order to increase the model fit to accommodate trends in the
two groups, both linear and quadratic terms for day of infection
are included in the model. Additionally, we limited the values of
RMCBS scores to be non-negative.
Comparisons of RMCBS were also assessed at day 8 between
the control and the experimental group with t-test for Figure 1.
Finally, we compared the difference in the number of total
hemorrhages in the two groups of RMCBS scores (0–15 versus
16–20) using the Mann-Whitney U analysis (Figure 8B). All
statistical analyses were carried out using SAS/STAT software,
Version 9.2 of the SAS system for UNIX, and the results were
graphed using SAS/GRAPH (SAS Institute, Cary, NC).
Supporting Information
Video S1 RMCBS Training Video. This training video covers
the 10 parameters used in the RMCBS. Video and audio are used
to demonstrate each parameter. A full scoring session is
demonstrated for a single subject, as well. A higher resolution
video file (336MB) can be downloaded (Video S2), or requested
from corresponding author RWC.
Found at: doi:10.1371/journal.pone.0013124.s001 (10.55 MB
MOV)
Video S2 High-resolution RMCBS Training Video. Higher
resolution version of Video S1. 336MB video file.
Found at: doi:10.1371/journal.pone.0013124.s002 (343.25 MB
MOV)
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